作者: Shigemasa Tani , Ikuyoshi Watanabe , Takeo Anazawa , Hirofumi Kawamata , Eizo Tachibana
DOI: 10.1016/J.AMJCARD.2005.05.069
关键词:
摘要: We hypothesized that a reduction in atherogenic malondialdehyde-modified low-density lipoprotein (MDA-LDL) levels, which may antagonize the action of atheroprotective high-density cholesterol, leads to coronary plaque regression. This study investigated effects pravastatin on serum levels MDA-LDL and atherosclerosis. In 6-month prospective study, 75 patients with stable artery disease were randomly assigned pravastatin-treatment group (n = 52) or control 23). Volumetric analyses performed matched segments by 3-dimensional intravascular ultrasound. Pravastatin therapy for 6 months resulted decrease volume (14.4%, p